We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Tests Detect Epstein Bar and BK Viruses

By LabMedica International staff writers
Posted on 04 May 2011
Molecular tests aid in detecting infectious disease viruses for organ transplant and other immunocompromised patients.

Two new Simplexa-branded molecular test kits enable hospital labs to perform advanced molecular testing for Epstein-Barr (EBV) and BK viruses. They are the first products from the Simplexa line to aid in the clinical management of patients with compromised immunity.

Simplexa tests, running on the 3M Integrated Cycler, employ real-time polymerase chain reaction (RT-PCR) diagnostic technologies to detect viruses, bacteria, and other agents qualitatively and quantitatively. The EBV test is performed on whole blood specimens and the BK virus test is performed on either urine or plasma specimens to quantitatively detect the viruses.

Most healthy people are infected with EBV and BK polyomavirus at some point during their lives. After the primary infection, the viruses typically become latent in the body. However, the viruses can reactivate when the immune system is significantly weakened, for example after organ transplantation, and cause fever, organ rejection, and even death.

Quest Diagnostics Inc., (Madison, NJ, USA) a provider of diagnostic testing, information, and services, announced that the two new Simplexa-branded molecular test kits developed by its Focus Diagnostics (Cypress, CA, USA) business have been CE marked for distribution to approximately 35 countries in Europe.

"The success of solid organ transplantation can hinge on how well a physician detects and prevents complications from infectious diseases like EBV and BK," said John G Hurrell, PhD, vice president and general manager, Focus Diagnostics. "CE marking of our new Simplexa EBV and BK virus tests will enable hospital and other labs in Europe to generate reliable results quickly in their own labs, an important advantage for managing these patients."

In April 2011, the Simplexa/3M technology won a 2011 Edison Award for new science and medical diagnostic product, based on criteria that included technological innovation and marketplace success.

Related Links:
Quest Diagnostics
Focus Diagnostics


New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Unit-Dose Packaging solution
HLX
New
Stand-Alone Disc Remover
NS96
New
DNA topoisomerase I ELISA
Anti-Scl-70 ELISA Test

Latest Molecular Diagnostics News

POC Sepsis Test Delivers Fast, Accurate and User-Friendly Results in Critical Care Settings

Experimental Blood Test Improves Detection of Early-Stage Pancreatic Cancer

Simple Blood Draw Helps Diagnose Lung Cancer 10 Times Faster